Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCL

Partner | Cancer Centers | <b>John Theurer Cancer Center</b>

Andre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.

Andre H. Goy, MD, physician in chief, Hackensack Meridian Health Oncology Care Transformation Service, chairman and chief physician officer, John Theurer Cancer Center, Lydia Pfund Chair for Lymphoma, academic chairman oncology, Hackensack Meridian School of Medicine at Seton Hall University, and professor of medicine, Georgetown University, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma (MCL).

Though the data is early, BTK inhibitors appear to have activity as maintenance therapy in MCL, explains Goy.

A study from the European MCL Intergroup is evaluating ibrutinib (Imbruvica) as maintenance therapy in patients who had an autologous stem cell transplant after rituximab (Rituxan), with cyclophosphamide, doxorubicin, vincristine, and prednisone, R-BAC (rituximab, bendamustine, and cytarabine), and transplant induction, concludes Goy.